Menu
Back to Journals » Clinical Interventions in Aging » Volume 3 » Issue 4
Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment
Authors Gagnon C, Li V, Ebeling PR
Published 5 December 2008 Volume 2008:3(4) Pages 635—645
DOI https://doi.org/10.2147/CIA.S3372
Review by Single anonymous peer review
Peer reviewer comments 4
Claudia Gagnon, Vivien Li, Peter R Ebeling
Department of Medicine, University of Melbourne, Melbourne, Australia
Abstract: As the population ages, the burden of osteoporosis in men is expected to rise. Implementation of preventive measures such as falls prevention strategies, exercise and adequate calcium and vitamin D intake is recommended. However, when the diagnosis of osteoporosis is made, effective treatments need to be initiated to prevent fractures. As opposed to postmenopausal women, reduced bone formation is the predominant mechanism of age-related bone loss in men, making anabolic agents a logical treatment option for men with osteoporosis. Teriparatide is the only anabolic agent currently approved for treatment of osteoporosis in men. This paper summarizes the mechanism of action of teriparatide, as well as its tolerability and safety. Furthermore, the evidence supporting the efficacy of teriparatide treatment in men with osteoporosis is reviewed and its current role in the management of osteoporosis in men is discussed.
Keywords: osteoporosis, pathophysiology, treatment, parathyroid hormone, men
© 2008 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.